Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression

Conclusion:
The observed decline in trial ARRs may result from decreasing pre-trial ARRs and a shorter time period over which pre-trial ARRs were calculated. Increasing patient age and duration of illness may also contribute.

Source: Multiple Sclerosis - October 16, 2013 Category: Neurology Authors: Steinvorth, S. M., Rover, C., Schneider, S., Nicholas, R., Straube, S., Friede, T. Tags: Research Papers Source Type: research